Alzheimer's Disease-Related Dementias Summit 2016: National research priorities

Roderick A Corriveau; Walter J Koroshetz; Jordan T Gladman; Sophia Jeon; Debra Babcock; David A Bennett; S Thomas Carmichael; Susan L-J Dickinson; Dennis W Dickson; Marian Emr; Howard Fillit; Steven M Greenberg; Michael L Hutton; David S Knopman; Jennifer J Manly; Karen S Marder; Claudia S Moy; Creighton H Phelps; Paul A Scott; William W Seeley; Beth-Anne Sieber; Nina B Silverberg; Margaret L Sutherland; Angela Taylor; Christine L Torborg; Salina P Waddy; Amelie K Gubitz; David M Holtzman

doi:10.1212/WNL.0000000000004717

Alzheimer's Disease-Related Dementias Summit 2016: National research priorities

Neurology. 2017 Dec 5;89(23):2381-2391. doi: 10.1212/WNL.0000000000004717. Epub 2017 Nov 8.

Authors

Roderick A Corriveau¹, Walter J Koroshetz², Jordan T Gladman², Sophia Jeon², Debra Babcock², David A Bennett², S Thomas Carmichael², Susan L-J Dickinson², Dennis W Dickson², Marian Emr², Howard Fillit², Steven M Greenberg², Michael L Hutton², David S Knopman², Jennifer J Manly², Karen S Marder², Claudia S Moy², Creighton H Phelps², Paul A Scott², William W Seeley², Beth-Anne Sieber², Nina B Silverberg², Margaret L Sutherland², Angela Taylor², Christine L Torborg², Salina P Waddy², Amelie K Gubitz², David M Holtzman²

Affiliations

¹ From the National Institute of Neurological Disorders and Stroke (R.A.C., W.J.K., J.T.G., S.J., D.B., M.E., C.S.M., P.A.S., B.-A.S., M.L.S., C.L.T., A.K.G.), Bethesda, MD; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.C.), David Geffen School of Medicine, University of California, Los Angeles; The Association for Frontotemporal Degeneration (S.L.-J.D.), Radnor, PA; Department of Neuroscience (D.W.D.), Mayo Clinic, Jacksonville, FL; The Alzheimer's Drug Discovery Foundation (H.F.); Icahn School of Medicine at Mount Sinai (H.F.), New York, NY; Department of Neurology (S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston; Eli Lilly and Company (M.L.H.), Lilly Research Centre, Erl Wood Manor, Windlesham, UK; Department of Neurology (D.S.K.), Mayo Clinic Rochester, MN; Taub Institute for Research on Alzheimer's Disease and the Aging Brain (J.J.M., K.S.M.) and College of Physicians and Surgeons (K.S.M.), Columbia University, New York, NY; National Institute on Aging (C.H.P., N.B.S.), Bethesda, MD; Memory and Aging Center, Department of Neurology (W.W.S.), and Department of Pathology (W.W.S.), University of California San Francisco; Lewy Body Dementia Association (A.T.), Lilburn, GA; National Institute of Diabetes and Digestive and Kidney Diseases (S.P.W.), Bethesda, MD; and Knight Alzheimer's Disease Research Center (D.M.H.), Hope Center for Neurological Disorders (D.M.H.), and Department of Neurology (D.M.H.), Washington University in St. Louis, MO. [email protected].
² From the National Institute of Neurological Disorders and Stroke (R.A.C., W.J.K., J.T.G., S.J., D.B., M.E., C.S.M., P.A.S., B.-A.S., M.L.S., C.L.T., A.K.G.), Bethesda, MD; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Department of Neurology (S.T.C.), David Geffen School of Medicine, University of California, Los Angeles; The Association for Frontotemporal Degeneration (S.L.-J.D.), Radnor, PA; Department of Neuroscience (D.W.D.), Mayo Clinic, Jacksonville, FL; The Alzheimer's Drug Discovery Foundation (H.F.); Icahn School of Medicine at Mount Sinai (H.F.), New York, NY; Department of Neurology (S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston; Eli Lilly and Company (M.L.H.), Lilly Research Centre, Erl Wood Manor, Windlesham, UK; Department of Neurology (D.S.K.), Mayo Clinic Rochester, MN; Taub Institute for Research on Alzheimer's Disease and the Aging Brain (J.J.M., K.S.M.) and College of Physicians and Surgeons (K.S.M.), Columbia University, New York, NY; National Institute on Aging (C.H.P., N.B.S.), Bethesda, MD; Memory and Aging Center, Department of Neurology (W.W.S.), and Department of Pathology (W.W.S.), University of California San Francisco; Lewy Body Dementia Association (A.T.), Lilburn, GA; National Institute of Diabetes and Digestive and Kidney Diseases (S.P.W.), Bethesda, MD; and Knight Alzheimer's Disease Research Center (D.M.H.), Hope Center for Neurological Disorders (D.M.H.), and Department of Neurology (D.M.H.), Washington University in St. Louis, MO.

Abstract

Goal 1 of the National Plan to Address Alzheimer's Disease is to prevent and effectively treat Alzheimer disease and Alzheimer disease-related dementias by 2025. To help inform the research agenda toward achieving this goal, the NIH hosts periodic summits that set and refine relevant research priorities for the subsequent 5 to 10 years. This proceedings article summarizes the 2016 Alzheimer's Disease-Related Dementias Summit, including discussion of scientific progress, challenges, and opportunities in major areas of dementia research, including mixed-etiology dementias, Lewy body dementia, frontotemporal degeneration, vascular contributions to cognitive impairment and dementia, dementia disparities, and dementia nomenclature.

Publication types

Review

MeSH terms

Alzheimer Disease / genetics
Alzheimer Disease / prevention & control
Alzheimer Disease / therapy*
Dementia / prevention & control
Dementia / therapy
Goals
Humans
Research
United States